



August 12, 2021

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject : Press release**

**Stock Code : BSE – 539787, NSE – HCG**

We wish to inform you that the Board of Directors of the Company, at their meeting held on August 12, 2021, *inter alia*, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2021.

In this respect, we enclose herewith the communication being released to the Press on the Financial Results of the Company for the quarter ended June 30, 2021.

Request you to take this on record.

Thanking you,

**For HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

**Encl: a/a.**

**HealthCare Global Enterprises Limited**

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

## HealthCare Global Enterprises Ltd. reports Q1 FY22 results

**Revenue for Q1 FY22 of INR 3,231 Million, a growth of 67% (y-o-y) and 8.4% (q-o-q)  
EBITDA for Q1 FY22 of INR 547 Million, a growth of 148% (y-o-y) and 25% (q-o-q)**

**Bengaluru, August 12, 2021: HealthCare Global Enterprises Limited (“HCG”)**, the leader in India in speciality healthcare services focused on oncology and fertility today announced its financial results for the quarter (“Q1”) ended June 30, 2021.

### Highlights for quarter ended June 30<sup>th</sup>, 2021

- Consolidated Income from Operations (“Revenue”) was **INR 3,231 mn** as compared to **INR 1,935 mn** in the corresponding quarter of the previous year, reflecting a year-on-year growth of **67%**
- Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 547 mn**, as compared to **INR 221 mn** in the corresponding quarter of the previous year, a growth of **148%** year-on-year and **25%** quarter-on-quarter
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was **INR 512 mn**, as compared to **INR 194 mn** in the corresponding quarter of the previous year, a growth of **165%** year-on-year and **30%** quarter-on-quarter
- Operating EBITDA for Existing centers was **INR 531 mn**, a growth of **109%** year-on-year and **21%** quarter-on-quarter, reflecting an Operating EBITDA margin of **21%**
- Operating EBITDA loss from New center was **INR 19 mn**, as compared to loss of **INR 61 mn** in the corresponding quarter of the previous year and **INR 46 mn** in the previous quarter, a reduction of **68%** year-on-year and **58%** quarter-on-quarter
- Consolidated Profit after Taxes and Minority Interest (“PAT”) was a loss of **INR 96 mn**, as compared to loss of **INR 398 mn** in the corresponding quarter of the previous year, a reduction of **76%** year-on-year

INR million except earnings per share

Period ended Jun'21	Q1-FY22	Q1-FY21	Growth (y-o-y)
<b>Income from Operations</b>	<b>3,231</b>	<b>1,935</b>	<b>67.0%</b>
<b>EBITDA<sup>(1)</sup></b>	<b>547</b>	<b>221</b>	<b>147.5%</b>
EBITDA margin (%)	16.9%	11.4%	
<b>Operating EBITDA<sup>(2)</sup></b>	<b>512</b>	<b>194</b>	<b>164.5%</b>
Op. EBITDA margin (%)	15.9%	10.0%	
<b>PBT<sup>(3)</sup></b>	<b>(89)</b>	<b>(566)</b>	<b>NM</b>
PBT margin %	-2.8%	-29.3%	
<b>PAT<sup>(4)</sup></b>	<b>(96)</b>	<b>(398)</b>	<b>NM</b>
PAT margin %	-3.0%	-20.5%	
<b>Earnings per share (EPS)</b>	<b>(0.76)</b>	<b>(5.14)</b>	<b>NM</b>

(1) Profit before depreciation and amortization, finance costs, exceptional items and taxes

(2) EBITDA excluding other income

(3) Profit / (Loss) before tax and after share of profit / (loss) of equity accounted investee

(4) Profit / (Loss) for the period after share of profit / (loss) of equity accounted investee, taxes and minority interests

## Business Updates for Q1 FY22

- Record performance with 'all-time high' operating financials delivered across the business:
  - Highest ever monthly and quarterly Revenue and EBITDA delivered during the quarter
  - Strong sequential & annual revenue growth, inspite of lower than industry impact in previous year
- HCG New centers continued their scale-up trajectory:
  - Strong revenue growth of **124%** y-o-y and **30%** q-o-q
  - Reduced losses with several centers achieving operating EBITDA break-even (unit level)
- Amidst COVID-led disruptions, several regions delivered double-digit revenue growth on sequential basis
  - Gujarat demonstrated growth across oncology and multi-specialty businesses, with revenue growth of **14.8%** q-o-q
  - Maharashtra saw strong ramp-up across all centers delivering **15.2%** revenue growth q-o-q
  - New oncology center in Jaipur delivered **18.8%** q-o-q revenue growth
- Continue to drive clinical excellence and patient care across businesses
  - Setup Mucormycosis 'Black fungus' treatment program with highest procedures & best outcomes
  - Actively drove vaccination programs across regions; contributed ~3% of revenues for the quarter
  - Milann maintained profitability in operations inspite of 2<sup>nd</sup> wave and strengthened clinical talent

Commenting on the results, **Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd.** said, "We are pleased to report Q1 FY22 results having emerged with strong performance on all counts while weathering the 2<sup>nd</sup> wave of the pandemic. The quarter started with rising cases, travel restrictions and lockdowns, which threatened to disrupt operations substantially, but we are proud to say that we were not only able to maintain continuity of treatment for cancer patients through usage of technology systems, but also ensured the highest quality of care. HCG has institutionalised tumour boards, research and academics across its centers and continues to bring globally comparable outcomes to every patient, along with creating last mile access and better quality of life. With growing oncology disease burden, the inherent strengths and future outlook of the HCG model is best suited to provide superior outcomes for patients while sustainably achieving the desired objectives of all stakeholders, over the coming years."

**Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd.**, added, "We are satisfied with the performance in Q1-FY22, which was also during one of the most testing times we may have seen in our lives. The fact that we have not only emerged successfully, but also created new performance benchmarks as an organization, is a testament to the clinical expertise and overall value proposition that we offer. HCG's large patient catchment of over 640mn population in states of presence and market position across these regions is a great platform helping us in redefining quality of care and outcomes at scale, thus driving clinical and geographic leadership. We continue to focus on disciplined capital allocation as we implement strategic initiatives across business development and digital health, while carrying strong momentum from Q1 into the current quarter. We are excited about the next few years as being truly transformative for HCG, to continue our dominant leadership in oncology, while delivering strong return on capital and meeting our responsibilities towards all stakeholders."

### Earnings Conference Call

The company will conduct a one hour conference call at **1:00 PM IST on Friday August 13, 2021** where the management will discuss insights about the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is **+91 22 6280 1107 /+91 22 7115 8008**. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

### About HCG Enterprises Ltd.

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under the "Milann" brand, HCG operates 7 fertility centers. Strand Life Sciences, an associate company of HCG, is a precision diagnostics company with strong track record in bioinformatics and a pioneer of genomic testing in India. **For further information, visit [www.hcgel.com](http://www.hcgel.com) or contact: Company Secretary and Compliance Officer: [Sunu Manuel, investors@hcgoncology.com](mailto:Sunu.Manuel@hcgoncology.com)**